As China rises to second place, next only to the U.S., for innovative new drugs, a new report by Clarivate – A Decade of Innovation, A Decade to Come – outlines key policy reforms and regulatory, R&D and investment trends driving past and future growth of Chinese biopharmaceuticals.

Biosion Inc. is getting more than $40 million in cash up front from Aclaris Therapeutics Inc. for the rights to develop two antibodies. The regulatory and sales milestones could also bring Biosion another $900 million. The two assets are BSI-045B, a high affinity and high potency anti-TSLP monoclonal antibody, and BSI-502, a bispecific antibody directed against TSLP and IL4R.

As China rises to second place, next only to the U.S., for innovative new drugs, a new report by Clarivate – A Decade of Innovation, A Decade to Come – outlines key policy reforms and regulatory, R&D and investment trends driving past and future growth of Chinese biopharmaceuticals.

Numab Therapeutics AG and Kaken Pharmaceutical Co. Ltd. have signed a new collaboration and option agreement to develop ND-081, a multispecific antibody for the treatment of inflammatory bowel disease.

Cstone Pharmaceuticals Co. Ltd. presented preclinical data of CS-2009, a trispecific antibody targeting PD-1, CTLA-4 and VEGF-A, for cancer immunotherapy.

University of Auckland senior research fellow Jeff Smaill first visited China in 2012 as part of a team of 15 scientists from the Maurice Wilkins Center, one of New Zealand’s centers of excellence, to meet with scientists at the Guangzhou Institute of Medicine and Health to find partners to collaborate on drug development projects. The scientists started collaborating that year, and the first project is already in phase I trials in China. It was a joint discovery and development partnership from the beginning, he said.

University of Auckland senior research fellow Jeff Smaill first visited China in 2012 as part of a team of 15 scientists from the Maurice Wilkins Center, one of New Zealand’s centers of excellence, to meet with scientists at the Guangzhou Institute of Medicine and Health to find partners to collaborate on drug development projects. The scientists started collaborating that year, and the first project is already in phase I trials in China. It was a joint discovery and development partnership from the beginning, he said.

Genome & Co. Ltd. has reported preclinical findings of its anti-CNTN4 antibody, GENA-104A16, and anti-APP antibody, 5A7 — stressing the contactin-4 (CNTN4) and amyloid precursor protein (APP) axis as a potential target for immuno-oncology. In the latest murine experiments, investigators led by Genome executives and researchers of Gwangju Institute of Science and Technology (GIST) found that blocking the interaction between CNTN4 and APP promoted cancer-destroying responses in mice, suggesting the pathway as a target for immunotherapy.